Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
The time of stem cell harvest and the mobilization regimen may play important roles in terms of achieving adequate numbers of stem cells by leukapheresis. To optimize the timing of leukapheresis, we have determined simultaneously the number of CD34+ cells in the peripheral blood as well as in the leukapheresis product of 214 apheresis procedures performed in 66 unselected patients with malignant hematologic diseases and solid tumors. A significant correlation between the number of CD34+ cells in peripheral blood and the leukapheresis product (R = 0.8) was found. The presence of more than 20 x 10(3)/ml blood CD34+ cells gave a sufficient yield (> or = 1.0 x 10(6) CD34+ cells/kg) in 81% of the cases. In an attempt to compare two priming regimens, we performed leukapheresis twice in 12 patients with stable disease. In the first sequence, stem cells were mobilized with rhG-CSF (10 micrograms/kg/day) alone and, in the second sequence, with cyclophosphamide (4 g/m2) plus rhG-CSF. A significantly higher yield of CD34+ cells and a better correlation between CD34+ cells in the peripheral blood and the leukapheresis product were found after priming with high-dose cyclophosphamide plus rhG-CSF, compared with priming with rhG-CSF alone. In a multivariate analysis, three factors were found to correlate with the yield of CD34+ cells, namely prior chemotherapy, bone marrow function, and the mobilization regimen. The use of cyclophosphamide priming improves CD34+ mobilization, and the introduction of blood CD34+ level optimizes the timing for harvest of stem cells, which should be performed early during treatment of malignancies.
Knudsen
L M
LM
Department of Haematology L, Herlev Hospital, University of Copenhagen, Denmark.
Gaarsdal
E
E
Jensen
L
L
Nielsen
K J
KJ
Nikolaisen
K
K
Johnsen
H E
HE
D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001773:Blood Cells; D001804:Blood Transfusion, Autologous; D001853:Bone Marrow / Q000187:drug effects*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000494:pharmacology; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004357:Drug Synergism; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D000069585:Filgrastim; D005472:Fluorouracil / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000097:blood / Q000628:therapy; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D007937:Leukapheresis; D007958:Leukocyte Count; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D011994:Recombinant Proteins
D018952:Antigens, CD34; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D000069585:Filgrastim; D008558:Melphalan; D005472:Fluorouracil; D002330:Carmustine